About
Investors

Investors

Leading a transformational approach to cell and gene therapies for diseases of the skin and connective tissue

 

Fibrocell is a cell and gene therapy company focused on improving the lives of people with rare diseases of the skin and connective tissue. The Company is utilizing its proprietary autologous fibroblast technology to develop personalized biologics that target the underlying cause of disease. Fibrocell’s pipeline of localized gene therapy candidates include FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a life-threatening genetic disorder diagnosed in infancy with no cure or treatment approved by the U.S. Food and Drug Administration. Fibrocell is also developing FCX-013 for the treatment of moderate to severe localized scleroderma. For more information, visit www.fibrocell.com or follow us on Twitter at @Fibrocell.

 
 
Events
Webcast
2019 BIO International Convention
Tuesday, June 4, 2019 at 1:00 PM EDT

Stock Quote

| (Common Stock)

Copyright West LLC. Minimum 15 minutes delayed.

Recent Happenings


Our News and Events

May 30, 2019
EXTON, Pa. , May 30, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski , President and Chief Executive Officer, will present
    Press Release

Tuesday, June 4, 2019 at 1:00 PM EDT

View Event
Philadelphia, PA
    Event